Zoldonrasib elicits objective responses in patients with KRAS G12D-mutated lung cancer: Phase I trial
Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib, according to results presented at ...
Apr 29, 2025
0
19









